Skip to main
FULC

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 56%
Sell 22%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company with a promising product candidate, Pociredir, in development for sickle cell disease (SCD). However, the recent discontinuation of the SCD program due to FDA feedback raises concerns about the company's pipeline and its ability to create value in the near-term. With limited visibility and the need for cost-cutting and strategic alternatives, a cautious stance is warranted and we are downgrading our rating to Market Perform with a $4 price target.

Bears say

Fulcrum Therapeutics is facing multiple risks related to its clinical, regulatory, and financial performance, which could negatively impact the stock. The discontinuation of its lead product candidate, Pociredir, for the treatment of sickle cell disease due to safety concerns raised by the FDA is a major setback for the company. With a projected mid-2027 cash balance of $234 million and a lack of strategic alternatives in sight, the stock's price target is cut to $3 from $23. Additionally, Fulcrum might require additional capital, posing a risk to achieving its price target.

FULC has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Hold based on their latest research and market trends.

According to 9 analysts, FULC has a Hold consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.